Pacific BiosciencesPACB
PACB
About: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Employees: 796
0
Funds holding %
of 6,780 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
33% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 4 (+1) [Q3]
17% more capital invested
Capital invested by funds: $336M [Q2] → $394M (+$58.2M) [Q3]
0% less funds holding
Funds holding: 225 [Q2] → 224 (-1) [Q3]
4% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 26
9% less call options, than puts
Call options by funds: $3.32M | Put options by funds: $3.63M
5.07% less ownership
Funds ownership: 90.1% [Q2] → 85.04% (-5.07%) [Q3]
14% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 77
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2
9%
upside
Avg. target
$3.50
90%
upside
High target
$6
226%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
UBS John Sourbeer 0% 1-year accuracy 0 / 3 met price target | 9%upside $2 | Neutral Downgraded | 11 Nov 2024 |
Scotiabank Sung Ji Nam 62% 1-year accuracy 13 / 21 met price target | 226%upside $6 | Sector Outperform Maintained | 11 Nov 2024 |
Piper Sandler David Westenberg 50% 1-year accuracy 8 / 16 met price target | 36%upside $2.50 | Neutral Maintained | 11 Nov 2024 |
Financial journalist opinion
Based on 12 articles about PACB published over the past 30 days
Negative
Seeking Alpha
2 weeks ago
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition
Pacific Biosciences of California stock surged 50% since August despite a 24% YoY revenue decline and deteriorating gross margins due to increased costs and pricing pressures. Q3 revenue of $40 million missed analyst estimates, with SG&A expenses surpassing total revenue and gross profit margins remaining low at 28%. Pacific Biosciences has made significant cuts in R&D, which may harm long-term growth given the rapid technological advancements in the genomic market.
Positive
The Motley Fool
3 weeks ago
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The rock star money manager is starting to roll with the rallying market.
Neutral
GlobeNewsWire
3 weeks ago
PacBio to Present at Upcoming Investor Conferences
MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
Negative
Zacks Investment Research
3 weeks ago
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y
PacBio Q3 2024 revenues decline year over year. However, Consumable, and Service and other revenues increase.
Neutral
Seeking Alpha
3 weeks ago
Pacific Biosciences of California, Inc. (PACB) Q3 2024 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christian Henry - President and Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Kyle Nixon - Canaccord Mason Carrico - Stephens Dan Brennan - TD Cowen Jack Meehan - Nephron Research Subbu Nambi - Guggenheim Securities Madeline Mollman - Wolfe Research Operator Good day and welcome to the PacBio Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Positive
Zacks Investment Research
3 weeks ago
Pacific Biosciences (PACB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Negative
Zacks Investment Research
3 weeks ago
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.27 per share a year ago.
Neutral
GlobeNewsWire
3 weeks ago
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's remaining outstanding 1.50% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which PacBio will (i) issue $200 million principal amount of its 1.50% Convertible Senior Notes due 2029 (the “New Notes”), (ii) issue 20,451,570 shares (the “Shares”) of PacBio's common stock (“common stock”), and (iii) make a cash payment in the amount of $50 million (the “Cash Consideration”) in exchange for $459 million principal amount of the 2028 Notes (the “Exchange Transaction”), in a transaction exempt from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The Exchange Transaction is expected to close on or about November 21, 2024, subject to customary closing conditions.
Neutral
GlobeNewsWire
3 weeks ago
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory
Neutral
Accesswire
4 weeks ago
The Schall Law Firm Encourages Investors With Losses To Join An Inquiry Into Pacific Biosciences of California Inc For Fraud
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Charts implemented using Lightweight Charts™